The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

By D. J. Drucker, M. Nauck. The Lancet, 2006

3,807 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/65258bd0c1e6f04adf02cc6e497b6cbdf5da17e6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Ralph DeFronzo
2. J. Meier
3. Josephine M. Egan
4. Wook Kim
5. M. Nauck
6. S. Swallow
7. Nur Samsu
8. J. Lovshin

In Oncology

1. S. Swallow
2. Ralph DeFronzo
3. Nur Samsu
4. J. Meier
5. M. Nauck
6. D. J. Drucker
7. Josephine M. Egan
8. Wook Kim

In Surgery

1. Ralph DeFronzo
2. J. Meier
3. M. Nauck
4. Josephine M. Egan
5. Wook Kim
6. S. Swallow
7. Nur Samsu
8. J. Lovshin

Citations in the corpus

• The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives (2018, background): “Preliminary data in humans demonstrate a possible improvement on the circulating biomarkers of inflammation by SGLT2-inhibitors; however, more studies are needed.(152)”
• Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2 (2012, methodology): “performed for the DCt data and only converted to relative expression levels (2) for presentation in the Figures.”
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “One of the reasons frequently given for using exenatide or DPP4 inhibitors is that they lead to “normalization” of incretin levels that are supposedly reduced compared with nondiabetic subjects (Drucker and Nauck, 2006).”
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, background): “However, in short-term studies, from several months to 1 year, both sitagliptin and vildagliptin (98,99,299,300) reduce the postprandial plasma glucose concentration while maintaining the plasma insulin response, indicating a positive effect on FIG.”
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes (2008, neutral): “Noncompliance 2 (1) 4 (2) 4 (2) 5 (2) 4 (3)”
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “Weight loss induced by GLP-1 RAs Intracerebroventricular [62] and peripheral administration of GLP-1 [12] and GLP-1 RAs [20,63] reduces appetite and prospective food consumption, increases satiety and a feeling of abdominal fullness, and limits caloric intake under conditions of ad libitum feeding.”
• TGR5-mediated bile acid sensing controls glucose homeostasis. (2009, background): “TGR5-mediated effects of BAs appear to center on the stimulation of GLP-1 release and the subsequent improvement in insulin secretion and pancreatic function (Drucker, 2006; Drucker and Nauck, 2006).”
• Incretin-based therapies for type 2 diabetes mellitus (2009, background): “These findings led to the discovery and generation of structurally distinct GLP-1 receptor (GLP-1R) agonists, which mimic the actions of GLP-1 in vivo in humans”
• Fluorine in medicinal chemistry. (2015, background): “The search for oral DPP-IV inhibitors was based on the laboratory observation that DPP-IV inhibitors caused an increase in insulin secretion, a process believed to be mediated primarily by inhibiting the proteolytic cleavage of the incretin hormone glucagon-like peptide-1 (GLP-1), a DPP-IV substrate”
• An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans (2017, neutral): “receptor (the target for a major class of T2D therapies (40)) is more directly implicated in”
• Gut Microbiota and Immune System Interactions (2020, background): “Furthermore, GLP-1 mimetics and a dipeptidyl peptidase-4 inhibitor are commonly used therapeutic approaches in clinics [105].”
• Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion (2011, background): “Both GIP and GLP-1 trigger glucosedependent insulin secretion, and although the effectiveness of GIP is impaired in people with type 2 diabetes (40), the preserved insulinotropic effect of GLP-1 (40) has led to the successful development of GLP-1 mimetics and DPP-IV inhibitors as new classes of anti”